Physicians' Academy for Cardiovascular Education

Long-term Treatment With Evolocumab in Patients With Homozygous Familial Hypercholesterolaemia (HoFH): Interim Results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG) Study

Slides (presentation) - June 19, 2015

Presentation prepared and held by Prof. Frederick Raal (University of Witwatersrand, Johannesburg, South Africa) in Clinical Breakthroughs session: Modifying LDL cholesterol to prevent CV events, Tuesday, May 26, 2015 during ISA2015 (Amsterdam, The Netherlands).

To view slides, click on images

ISA_LS_2015p_TAUSSIG_long_term_Raal.pdf (0,4MB)ISA_LS_2015p_TAUSSIG_long_term_Raal.pdf (0,4MB)